Earnings summaries and quarterly performance for AMGEN.
Executive leadership at AMGEN.
Robert A. Bradway
Detailed
Chief Executive Officer and President
CEO
DM
David M. Reese
Detailed
Executive Vice President and Chief Technology Officer
JE
James E. Bradner
Detailed
Executive Vice President, Research and Development
MG
Murdo Gordon
Detailed
Executive Vice President, Global Commercial Operations
PH
Peter H. Griffith
Detailed
Executive Vice President and Chief Financial Officer
Board of directors at AMGEN.
AE
Amy E. Miles
Detailed
Director
BJ
Brian J. Druker
Detailed
Director
CM
Charles M. Holley, Jr.
Detailed
Director
EJ
Ellen J. Kullman
Detailed
Director
GC
Greg C. Garland
Detailed
Director
ME
Mary E. Klotman
Detailed
Director
MV
Michael V. Drake
Detailed
Director
RA
Robert A. Eckert
Detailed
Lead Independent Director
SO
S. Omar Ishrak
Detailed
Director
TJ
Tyler Jacks
Detailed
Director
WM
Wanda M. Austin
Detailed
Director
Research analysts who have asked questions during AMGEN earnings calls.
CS
Christopher Schott
JPMorgan Chase & Co.
6 questions for AMGN
Also covers: ABBV, AMRX, BIIB +15 more
Jay Olson
Oppenheimer & Co. Inc.
6 questions for AMGN
Also covers: ACAD, BIIB, BNTX +22 more
Salveen Richter
Goldman Sachs
6 questions for AMGN
Also covers: ACAD, AGIO, ALLO +20 more
Terence Flynn
Morgan Stanley
6 questions for AMGN
Also covers: ABBV, ARVN, BIIB +17 more
YW
Yaron Werber
TD Cowen
6 questions for AMGN
Also covers: ALEC, ARGX, ASND +14 more
David Amsellem
Piper Sandler Companies
5 questions for AMGN
Also covers: ABBV, ALKS, AMPH +27 more
ES
Evan Seigerman
BMO Capital Markets
5 questions for AMGN
Also covers: ABBV, ARVN, BIIB +15 more
Matthew Phipps
William Blair
5 questions for AMGN
Also covers: ABBV, AGEN, ARGX +8 more
DR
David Risinger
Leerink Partners
4 questions for AMGN
Also covers: ABBV, BMY, HALO +9 more
AH
Alexandria Hammond
Wolfe Research
3 questions for AMGN
Also covers: ABBV, BMRN, BMY +6 more
CB
Courtney Breen
AllianceBernstein
3 questions for AMGN
Also covers: ABBV, BMY, GILD +4 more
Gregory Renza
RBC Capital Markets
3 questions for AMGN
Also covers: ACAD, ADCT, AGIO +12 more
Michael Yee
Jefferies
3 questions for AMGN
Also covers: ALLO, BEAM, BIIB +14 more
UR
Umer Raffat
Evercore ISI
3 questions for AMGN
Also covers: ALKS, BHC, BIIB +15 more
CL
Carter L. Gould
Barclays
2 questions for AMGN
Also covers: ABBV, ALEC, BMY +7 more
Mohit Bansal
Wells Fargo & Company
2 questions for AMGN
Also covers: ABBV, BMRN, BMY +16 more
CR
Christopher Raymond
Piper Sandler
1 question for AMGN
Also covers: ABBV, AGIO, ARDX +7 more
Conor MacKay
BMO Capital Markets
1 question for AMGN
Also covers: ABCL, ARVN, INCY
Geoff Meacham
Citigroup Inc.
1 question for AMGN
Also covers: ABBV, BMY, GILD +8 more
JS
James Shin
Analyst
1 question for AMGN
Also covers: ABBV, AUTL, BMY +7 more
LI
Luca Issi
RBC Capital Markets
1 question for AMGN
Also covers: ADVM, ALLO, ALNY +12 more
Michael DiFiore
Evercore ISI
1 question for AMGN
Also covers: AMLX, BIIB, ELAN +8 more
Mike DiFiore
Evercore ISI
1 question for AMGN
Also covers: RPRX
OB
Olivia Brayer
Cantor
1 question for AMGN
Also covers: AUPH, BMRN, BMY +8 more
SR
Sadia Rahman
Wells Fargo
1 question for AMGN
Also covers: HALO, MLYS, TVTX
TA
Timothy Anderson
BofA Securities
1 question for AMGN
Also covers: ABBV, AZN, BIIB +10 more
TH
Trung Huynh
UBS Group AG
1 question for AMGN
Also covers: ABBV, ABOS, BMY +5 more
Recent press releases and 8-K filings for AMGN.
Amgen takes action with U.S. government to lower medicine costs
AMGN
New Projects/Investments
Product Launch
- Amgen has agreed to implement the U.S. Administration’s Most Favored Nation pricing requests outlined in President Trump’s July 31 letter to lower medicine costs for American patients.
- The company will expand its AmgenNow™ direct-to-patient program to include Aimovig® and Amjevita® at $299/month, about 60% and 80% discounts off current list prices, respectively; Repatha® was previously made available at $239/month in October 2025.
- Since 2018, Amgen has invested over $40 billion in U.S. manufacturing and R&D; in 2025 alone it committed an additional $2.5 billion for facility expansions in Ohio and North Carolina and secured three years of tariff relief.
Dec 19, 2025, 7:23 PM
Amgen: Global Gene Therapy Market to Reach USD 36.55 Billion by 2032
AMGN
New Projects/Investments
- Global gene therapy market grew from US$7.21 billion in 2023 to US$8.85 billion in 2024 and is projected to reach US$36.55 billion by 2032 at a 19.4% CAGR.
- Growth driven by rising demand for curative and precision-based therapies, with about 19 new gene therapy launches expected between 2026 and 2032.
- High development and pricing barriers, with gene therapy development costs up to US$5 billion and therapies like Pfizer’s Beqvez (~US$3.5 million) and Lenmeldy (~US$4.25 million) facing reimbursement challenges.
- Viral vectors were the largest segment in 2023, neurology led therapeutics, and North America remained the largest regional market.
- Strategic initiatives include Amgen’s US$1 billion manufacturing expansion, while the competitive landscape is led by Biogen, Novartis, Alnylam, Sarepta, and others.
Dec 15, 2025, 2:30 PM
Amgen’s UPLIZNA approved by FDA for generalized myasthenia gravis
AMGN
Product Launch
- FDA approved UPLIZNA® (inebilizumab-cdon) for generalized myasthenia gravis in adults positive for anti-AChR and anti-MuSK antibodies, the first CD19-targeted B-cell therapy in this indication.
- The regimen consists of two loading doses followed by two annual maintenance infusions, compared with dosing intervals of 2–8 weeks for competing treatments.
- Approval leverages UPLIZNA’s established safety and efficacy in neuromyelitis optica spectrum disorder and IgG4-related disease, broadening Amgen’s autoimmune neuromuscular portfolio.
Dec 12, 2025, 5:43 PM
Amgen receives FDA approval for UPLIZNA in gMG
AMGN
Product Launch
- The FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, with twice-yearly maintenance dosing after two loading doses.
- UPLIZNA is the first and only CD19-targeted B cell therapy approved for gMG, depleting pathogenic B cells underlying disease pathology.
- In the Phase 3 MINT trial, UPLIZNA achieved a -4.2 vs -2.2 mean change in MG-ADL score at Week 26 (p<0.0001) and sustained benefit through Week 52 in AChR+ patients.
- This approval represents UPLIZNA’s third FDA indication, following its approval for NMOSD in June 2020 and for IgG4-RD in April 2025.
Dec 11, 2025, 11:09 PM
Prolynx secures $70M Series A and appoints Chris Boulton as CEO
AMGN
New Projects/Investments
Management Change
Board Change
- Closed a $70 million Series A financing co-led by 5AM Ventures and OrbiMed, with participation from Monograph Capital, to advance ultra-long-acting obesity and metabolic candidates.
- Appointed Chris Boulton, former Vice President and Global Marketing Therapy Area Head for Obesity at Amgen, as Chief Executive Officer to drive commercialization.
- Syndicate investors Kush Parmar (5AM Ventures), Peter Thompson (OrbiMed), and Fred Cohen (Monograph Capital) joined the board alongside independent director David Martin.
- Platform engineered for once-monthly and once-quarterly dosing of peptide therapeutics to improve adherence and tolerability in obesity treatment.
Dec 11, 2025, 12:00 PM
Amgen reports strong FY2025 growth and outlines pipeline and capital strategy
AMGN
Revenue Acceleration/Inflection
New Projects/Investments
- Amgen delivered 10% revenue growth through 9M 2025 (12% in Q3) driven by 11% product sales growth and 14% volume growth, reflecting its volume-focused strategy.
- The in-market portfolio features six key growth drivers: Repatha & Evenity +30% YTD, Tezspire +50%, rare disease (~ $5 bn annualized, +12%), innovative oncology +11%, and biosimilars +40% (~ $3 bn annualized).
- Pipeline advances include six Phase 3 Maritide studies (obesity/diabetes) with Phase 2 maintenance data expected in early 2026, Olpaceran Phase 3 Lp(a) trial (~ 7,300 pts), and multiple Imdeltra Phase 3 small-cell lung cancer studies.
- Capital allocation emphasizes mid-20s % R&D spending growth, ~$200 mn of Q3 business development, $2.2–2.3 bn capex on U.S. manufacturing expansions, and a wide BD aperture focused on innovation.
- Engaging with the U.S. administration on pricing policy, launched Amgen Now (Repatha at $2.39/mo direct-to-consumer), and managing Prolia/Xgeva biosimilar erosion alongside Evenity growth.
Dec 3, 2025, 6:45 PM
Amgen outlines FY 2025 performance and pipeline at Citi Global Healthcare Conference 2025
AMGN
New Projects/Investments
- Amgen delivered 10% revenue growth through the first nine months of FY 2025, including 11% product sales growth driven by 14% volume growth, and in Q3 reported 12% revenue growth on 14% volume growth.
- The in-line portfolio’s six major growth drivers posted YTD gains of Repatha +30%, Evenity +30%, TESSPIRE +50% (now $1 B in U.S. sales), rare disease +12% (annualizing near $5 B), innovative oncology +11%, and biosimilars +40%.
- Innovation remains top priority with non-GAAP R&D up 31% in Q3 and a mid-20% R&D spend target for FY 2025; key programs include six global Phase III studies for Meritide, Phase III for opaciran, and bispecific T-cell engager trials in small cell lung and prostate cancers.
- Capital allocation focuses on internal/external innovation: $2.2–2.3 B CapEx guide, $200 M of business development in Q3, ongoing debt reduction post-Horizon, and a wide BD pipeline with high standards.
- Amgen continues productive policy engagement, launched Amgen Now direct-to-consumer Repatha at $2.39/month via GoodRx, and is exploring expanded access models for future products.
Dec 3, 2025, 6:45 PM
Amgen presents strong FY 2025 momentum and pipeline updates at Citi Healthcare Conference
AMGN
Revenue Acceleration/Inflection
New Projects/Investments
- Amgen reported 10% revenue growth through the first nine months and 12% growth in Q3, driven by 14% volume gains, while non-GAAP R&D spending rose 31% in Q3 and is guided to mid-20% for FY 2025.
- The company’s six in-market growth drivers include Repatha (30% YTD growth), Evenity (30%), Tezspire (50%, $1 billion US sales), a $5 billion-annualized rare disease portfolio (Uplizna 50% growth; PDUFA Dec 14), innovative oncology (Imdeltra standard of care in 2L small-cell lung cancer) and a $3 billion biosimilars business (40% growth).
- Key pipeline programs advancing: Maritide with six global Phase 3 trials (weight management, CVD, HF, OSA) and Phase 2 maintenance data due in 2026; Olpaceran Lp(a) siRNA Phase 3 in 7,300 high-risk patients; Imdeltra Phase 3 front-line small-cell lung cancer studies; and Xyritamig Phase 3 in prostate cancer.
- Capital allocation remains innovation-first, with $2.2–2.3 billion CapEx for manufacturing expansion, ~$200 million of Q3 business development spend, and active US policy engagement—including the Amgen Now direct-to-consumer Repatha offering at $2.39/month.
Dec 3, 2025, 6:45 PM
Amgen details FY2025 revenue momentum, growth drivers, and pipeline at Citi conference
AMGN
- Amgen reported 10% revenue growth YTD through Q3, with 12% growth in Q3 driven by 14% volume increase as part of its volume-driven strategy.
- The company highlighted six core growth drivers, including Repatha (+30% Y/Y), Evenity (+30%), Tezspire (+50%), its rare disease portfolio (
$5 B, +12%), innovative oncology (Imdeltra/Blincyto, +11%), and biosimilars ($3 B, +40%). - Key pipeline updates include Repatha’s VESALIUS-CV trial showing 25% CV event reduction and 36% MI reduction, six phase 3 Maritide studies in weight management and comorbidities, Olpaceran Lp(a) siRNA in phase 3 with 95–100% knockdown, and Imdeltra’s phase 3 small-cell lung cancer trials.
- Innovation remains the top capital allocation priority, with R&D spend up mid-20% Y/Y, ~$200 M in Q3 business development, $2.2–2.3 B capex guide, and ongoing debt reduction.
- Amgen launched Amgen Now, a direct-to-consumer program offering Repatha at $2.39/month, expanding access and informing future consumer-facing initiatives.
Dec 3, 2025, 6:45 PM
Amgen updates growth drivers and pipeline at Evercore HealthCONx
AMGN
Revenue Acceleration/Inflection
New Projects/Investments
- Revenues up 10% through the first nine months of 2025 with 11% product sales growth and 14% volume growth; 12 products grew double-digits and 14 products are annualizing at >$1 bn, with 16 products posting double-digit growth in Q3.
- Outlined six key growth drivers: Repatha, Evenity, Tezspire, the innovative oncology portfolio, rare disease portfolio (annualizing at ~$5 bn), and biosimilars (annualizing at ~$3 bn).
- Repatha grew >30% YoY, now annualizing at ~$3 bn, supported by broad U.S. access and Vesalius-CV data demonstrating a 25% reduction in major adverse cardiovascular events and 36% reduction in heart attack risk.
- Pipeline progress includes six global Phase III trials for MariTide (weight management, cardiovascular, heart failure, sleep apnea), Phase III for Olpasiran (Lp[a] lowering), and late-stage development for Imdeltra, Blincito, and Xaluritamig bispecifics.
Dec 3, 2025, 3:00 PM
Quarterly earnings call transcripts for AMGEN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more